drugset / Trial / NCT02233699

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

NCT02233699 ↗

Phase 2 Completed 18 enrolled Xention Ltd Ario Pharma Ltd · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic idiopathic cough. The effectiveness of XEN-D0501 over placebo in reducing capsaicin cough responses, objective 24-hour cough frequency, hourly change in cough frequency, cough severity (via visual analogue scale \[VAS\]), urge to cough (via VAS), global rating of change scale and Leicester Cough Questionnaire (LCQ) will be evaluated.

Timeline

Start
2014-07
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject XEN-D0501 Unknown 4 mg —

Indications

No indication recorded.